Amarin Corporation plc Overview
Pro stress-test →Amarin Corporation is a pharmaceutical company focused on developing and pursuing additional therapeutics to cost-effectively address cardiovascular health worldwide. The company's flagship product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Strategic Profile
Pro stress-test →Amarin has entered 2026 from an improved position of market, operational, and financial strength, maintaining U.S. leading market share for VASCEPA and actively expanding presence in Europe for VAZKEPA. The company expects to generate positive cash flow for the full year in 2026 through cost-efficient revenue generation with its U.S. franchise and new international business model while operating with a significantly improved OpEx profile.
Competitive Landscape
Pro stress-test →Amarin competes in the cardiovascular pharmaceutical space with VASCEPA, selling principally through wholesalers, regional wholesalers, and specialty pharmacy providers. The company maintains market leadership in the prescription omega-3 segment while competing against other cardiovascular disease management therapies from major pharmaceutical firms.
Industry Context
Amarin Corporation plc operates in Cardiovascular Pharmaceuticals.
Key facts
Founded: 1989 · Headquarters: Dublin, Ireland · Revenue: $214M · Market cap: $276M